Posts in category Healthcare


Veeva Systems Inc (VEEV) Shares May Be Pricey in the Short-Term, But This Top Analyst Backs Long-Term Valuation Potential

Canaccord’s Richard Davis anticipates VEEV stock can move up consistently sometime by the first half of next year.

Read more

This Healthcare Analyst Pounds the Table on Revance Therapeutics Inc (RVNC)

Guggenheim’s Rohit Vanjani puts a price tag on Revance Therapeutics.

Read more

Adamis Pharmaceuticals Corp: Naloxone Could Be a Significant Growth Candidate, Says Elliot Wilbur

With the tremendous focus on the opioid crisis, Raymond James’ Elliot Wilbur sees exciting potential for Adamis.

Read more

Bluebird Bio Inc Gains a New Bull; John Newman Drawn to bb2121’s Long-Term Potential

Canaccord’s John Newman sees 24% upside potential for BLUE shares.

Read more

Tim Chiang Stays Sidelined When It Comes to Valeant Pharmaceuticals Intl Inc’s (VRX) Recovery, but Sings the Praises of Bausch & Lomb Business

BTIG’s Tim Chiang still spots challenges in VRX’s orbit, but likewise pinpoints strength in eyecare business Bausch + Lomb, which boasts robust international gains.

Read more

Adamis Pharmaceuticals Corp (ADMP): Analyst Sees Meaningful Revenue Gains Waiting in the Wings for Sympjepi Asset

Now that ADMP has submitted a PAS for its pediatric version of Symjepi, an epipnephrine injection cheaper than Mylan’s EpiPen, FBR’s Andrew D’silva sees a potential approval with less risk than the original version.

Read more

Gilead Sciences, Inc. Attracts a New Bull Thanks to “Gift” of Kite

Maxim’s McCarthy now sees 27% upside potential for Gilead, impressed with management’s plans for lymphoma asset Yescarta.

Read more

TherapeuticsMD Inc (TXMD): William Tanner Questions Bearish Voices as TX-004 Makes Its Way Closer to Gaining a Green Light

Cantor’s William Tanner smirks as bears run low on “ammunition” to doubt TXMD on the heels of news of an NDA resubmission to the FDA for TX-004.

Read more

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Gets a Price Target Boost After This Analyst Finds the Pharma Giant Is Safer from a Credit Downgrade

Mizuho’s Irina Rivkind Koffler may remain apprehensive on generics competition, but the analyst likes what she sees with new plans for corporate restructuring.

Read more

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Keeps This Bull Enthusiastic as CEO Kare Schultz Strides Towards Leaner Operating Structure

Teva has stirred up Street excitement with news of executive changes and an organizational overhaul.

Read more